Cell Therapy News/Articles, page-8248

@ddwn, yes, a cost-benefit analysis will have to be done. Injecting rex-L into a patient with NYHA class 2 CHF can be thought of as a form of treatment. But it can also be regarded as a form of "tertiary prevention". In doing our analysis we have to consider the costs of doing nothing. Or doing something inferior with a competing medication. That starts with a calculation of the full costs of taking care of a patient who is let's say 50 years old, and has a stroke with residual hemiplegia. Or worse. Full costs in terms of medical care and lost years of productivity, not to mention assigning some artificial monetary amount to the human tragedy of preventable suffering of patient, family and community. And when we find that benefits of rex-L outweigh costs in class 2 CHF, doctors and insurance companies will begin to look around for other patient categories that might benefit from such tertiary prevention... or even secondary prevention. I believe that's what SI was talking about in his presentation yesterday.